SCHEMBL5362148

SCHEMBL5362148

CCOC(=O)c1ccc2c(c1)C(=Cc1sccc1C)C(=O)N2

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.48
PDPK1 O15530 1/20 0.47
AURKA O14965 1/20 0.47
RAF1 P04049 1/20 0.47
TLK2 Q86UE8 6/20 0.47
GSK3B P49841 1/20 0.46
ALDH1A1 P00352 1/20 0.45
CDK1 P06493 2/20 0.45
CCNB1 P14635 2/20 0.45
JAK3 P52333 2/20 0.44
ABL1 P00519 1/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
FLT3 P36888 1/20 0.44
ALK Q9UM73 1/20 0.44
NEK2 P51955 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366782 0.89 PDPK1 (0.60) KDRPDPK1AURKARAF1TLK2
SCHEMBL5364206 0.88 JAK3 (0.47) KDRPDPK1AURKARAF1TLK2
SCHEMBL5359359 0.81 TLK2 (0.47) KDRPDPK1TLK2ALDH1A1JAK3
SCHEMBL5369648 0.80 TLK2 (0.74) KDRPDPK1AURKATLK2JAK3
SCHEMBL5365829 0.80 PDPK1 (0.48) KDRPDPK1AURKARAF1TLK2
SCHEMBL5358278 0.79 MEN1 (0.46) KDRPDPK1TLK2ALDH1A1RET
SCHEMBL5366152 0.78 GSK3B (0.51) KDRTLK2GSK3BJAK3RET
SCHEMBL5367344 0.78 GRK5 (0.51) KDRGSK3BALDH1A1JAK3PDGFRB
SCHEMBL5364695 0.78 RET (0.44) KDRPDPK1TLK2ALDH1A1RET
SCHEMBL5374151 0.77 PDPK1 (0.78) KDRPDPK1TLK2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KDR 239/4885PDPK1 31/4885AURKA 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.